Periodical
In VitroActivity of Pyronaridine against Multidrug-Resistant Plasmodium falciparumand Plasmodium vivax
| العنوان: | In VitroActivity of Pyronaridine against Multidrug-Resistant Plasmodium falciparumand Plasmodium vivax |
|---|---|
| المؤلفون: | Price, R. N., Marfurt, J., Chalfein, F., Kenangalem, E., Piera, K. A., Tjitra, E., Anstey, N. M., Russell, B. |
| المصدر: | Antimicrobial Agents and Chemotherapy; December 2010, Vol. 54 Issue: 12 p5146-5150, 5p |
| مستخلص: | ABSTRACTPyronaridine, a Mannich base antimalarial, has demonstrated high in vivoand in vitroefficacy against chloroquine-resistant Plasmodium falciparum. Although this drug has the potential to become a prominent artemisinin combination therapy, little is known about its efficacy against drug-resistant Plasmodium vivax. The in vitroantimalarial susceptibility of pyronaridine was assessed in multidrug-resistant P. vivax(n= 99) and P. falciparum(n= 90) isolates from Papua, Indonesia, using a schizont maturation assay. The median 50% inhibitory concentration (IC50) of pyronaridine was 1.92 nM (range, 0.24 to 13.8 nM) against P. falciparumand 2.58 nM (range, 0.13 to 43.6 nM) against P. vivax, with in vitrosusceptibility correlating significantly with chloroquine, amodiaquine, and piperaquine (rs[Spearman's rank correlation coefficient] = 0.45 to 0.62; P< 0.001). P. falciparumparasites initially at trophozoite stage had higher IC50s of pyronaridine than those exposed at the ring stage (8.9 nM [range, 0.6 to 8.9 nM] versus 1.6 nM [range, 0.6 to 8.9 nM], respectively; P= 0.015), although this did not reach significance for P. vivax(4.7 nM [range, 1.4 to 18.7 nM] versus 2.5 nM [range, 1.4 to 15.6 nM], respectively; P= 0.085). The excellent in vitroefficacy of pyronaridine against both chloroquine-resistant P. vivaxand P. falciparumhighlights the suitability of the drug as a novel partner for artemisinin-based combination therapy in regions where the two species are coendemic. |
| قاعدة البيانات: | Supplemental Index |
Full Text Finder | تدمد: | 00664804 10986596 |
|---|---|
| DOI: | 10.1128/AAC.00801-10 |